This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Crystal structures to guide the design of immunoproteasome-specific inhibitors	<p>Crystal structures of constitutive proteasomes and immunoproteasomes could guide the design of immunoproteasome-specific inhibitors. Constitutive proteasomes and immunoproteasomes are variants of the proteasome, and the latter are associated with cancer, inflammation and autoimmune diseases. Crystal structures were solved for murine constitutive proteasomes and immunoproteasomes with and without the immunoproteasome-selective inhibitor ONX-0914 (PR-957). Next steps could include using the structural insights to design more potent and selective immunoproteasome inhibitors.</p> <p>Onyx Pharmaceuticals Inc.'s ONX-0914 is in preclinical development for autoimmune diseases.</p> <p>SciBX 5(9); doi:10.1038/scibx.2012.241 Published online March 1, 2012</p>	Unpatented; unavailable for licensing	<p>Huber, E.M. <i>et al. Cell</i>; published online Feb. 17, 2012; doi:10.1016/j.cell.2011.12.030 Contact: Michael Groll, Technical University Munich, Munich, Germany e-mail: michael.groll@ch.tum.de Contact: Marcus Groettrup, University of Konstanz, Konstanz, Germany e-mail: marcus.groettrup@uni-konstanz.de</p>